In the worldwide race for a vaccine to stop the coronavirus, the laboratory sprinting fastest is at Oxford University.
Most other teams have had to start with small clinical trials of a few hundred participants to demonstrate safety. But scientists at the university’s Jenner Institute had a head start on a vaccine, having proved in previous trials that similar inoculations — including one last year against an earlier coronavirus — were harmless to humans.
That has enabled them to leap ahead and schedule tests of their new coronavirus vaccine involving more than 6,000 people by the end of next month, hoping to show not only that it is safe, but also that it works.
https://www.nytimes.com/2020/04/27/world/europe/coronavirus-vaccine-update-oxford.html
Met een stukje Hollandse glorie.
Ook in de race, eveneens testend op overuren draaiende resusapen, en inmiddels op mensen, is het Chinese Sinovac Biotech.
April 17, 2020 08:00 AM Eastern Daylight Time
BEIJING — Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company has commenced Phase I clinical trial, a randomized, double-blinded, placebo controlled study, for its vaccine candidate against COVID-19. Enrollment of the first group of volunteers and the first dose of vaccination for these volunteers have been completed.
This study is to evaluate the safety, tolerance, and preliminary immunogenicity of the Company’s SARS-CoV-2 vaccine by vaccinating 144 healthy adults, aged from 18 to 59, with two different dosages of the vaccine candidate. Two-thirds of the volunteers will be vaccinated with the investigational vaccine while one-third of volunteers will be administered with the placebo. The trial is being conducted in Jiangsu Province.
http://www.sinovac.com/?optionid=754&auto_id=897
Meer over (klinische) testfases >
https://www.als-centrum.nl/kennisplatform/wat-is-geneesmiddelenonderzoek/
